A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 08 Aug 2016 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 28 Apr 2016 Status changed from completed to active, no longer recruiting.
- 25 Apr 2016 Status changed from active, no longer recruiting to completed.